Genmab — Marts 2018

[Sukkeralf]

nice words: “This would be extremely practice-changing. Daratumumab has moved from monotherapy in advanced disease to first relapse. And now—at this year's ASH—we have newly diagnosed. That's a lot of dara[tumumab] being used globally. And to be giving a more convenient, potentially safer form of administration is really going to be very practice-changing.”

[E_L]

[E_L]

https://www.ncbi.nlm.nih.gov/pubmed/29500635?dopt=Abstract&utm_source=dlvr.it&utm_medium=twitter - Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions. Don't try to read this before you had your coffee....

[Bulder]

... and nice to know: The syringe pump is out of the picture with the 15 ml pre mixed vial. Could easily be administered at home by a nurse.

[Helge_LarsenPI-redaktør]

[OHW]

Lad os håbe, at alle de gode historier efterhånden vil kunne ses på salgstallene.

[E_L]

that is immediately what i thought about Bulder. How long ago did we ask Jan about home administration? I think you have your first question for Q&A Q1

[Bulder]

E L: Tried to read your link after one cup of coffee. Not enough. Then I added one Heineken. Didn't help. Then another Heineken. Nope. Then I gave up. What about you?

[E_L]

I started with the Heineken. Didn't help. Then another Heineken. Nope. So then I tried the coffee. No luck. Now just waiting for Sukkeralf to explain it to us

[Parasitism]

Jeg gider ikke engang prøve, når I to ikke kan udlede noget af det

[Bulder]

Jeg prøver alligevel: Er det noget med at man kan bruge NK-celler fra raske donorer til at modvirke at mikromiljøet omkring tumorerne hæmmer patientens egne NK-cellers aktivitet? Dara udvirker ADCC via NK-cellerne, men disse hæmmes af visse faktorer i mikromiljøet. Tilførsel af fremmede NK-celler kan således forstærke effekten af dara. ??

[Doc4]

...hvis nogen ønsker den fulde artikel...kræver STOR indsigt og viden om den meget specifikke terminology...https://sci-hub.hk/https://doi.org/10.1007/s00262-018-2140-1

[Bulder]

er jeg helt på vildspor, Doc4?

[Doc4]

...og her er en ny oversigtsartikel...'CD38-targeting antibodies in multiple myeloma:
mechanisms of action and clinical experience'....fuld artikel...https://sci-hub.hk/10.1080/1744666X.2018.1443809

[Doc4]

@Bulder..Min umiddelbare mening...tjae, nok noget;), men det er en særdeles vanskellig artikel og jeg har pt desværre ikke tid til nærlæsning:(. Dara, fx, i sig selv hæmmer/mindsker CD-38 receptorerne efter første infusion med 90%.

[gentogen]

Jeg læser det som dig Bulder, men pointen er vist på sin vis lidt den omvendte, at NK-terapi kan understøttes af forskellige ADCC 'triggering antibodies', hvor Dara er et eksempel

[Bulder]

Jo, men problemet er at CD38 også udtrykkes på NK-cellerne, hvorved dara selv er med til at mindske effekten af ADCC, fordi dara slår nogle af NK-cellerne ihjel. Derfor tilførsel af donor-NK-celler som kan igen forstærke ADCC-processen.

[Bulder]

Fra Doc4's link: In summary, we showed in this study that the combination
of an ADCC triggering antibody and selection of KIRligand
mismatched donors is a potent and realistic platform
to potentiate the NK cell antitumor response in the TME.

[Legolas23]

Altså effekt i solide - i teorien ?

[Bulder]

Mere af samme skuffe: The antitumor potential of
NK cells can be applied by donor NK-cell infusion as well
as by haploidentical stem-cell transplantation.